Clinical Trials Logo
  1. Home
  2. Papulopustular Rosacea
  3. NCT03864978

Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

Papulopustular Rosacea Clinical Trial

Official title:
Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients With Moderate-to-severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial

Clinical Trial Summary

Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea.

The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea (a.k.a. subtype II) and positive lactulose H2/CH4 breath test.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03864978
Study type Interventional
Source Alfasigma S.p.A.
Contact Alessandro Blè, MD
Phone +39-051-6489619
Email alessandro.ble@alfasigma.com
Status Recruiting
Phase Phase 2
Start date June 22, 2018
Completion date October 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03276936 - A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea Phase 3
Completed NCT02601963 - Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea Phase 2
Completed NCT02268474 - Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea N/A
Completed NCT01555463 - Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea Phase 3
Active, not recruiting NCT03667222 - Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea Phase 2
Terminated NCT03564145 - A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05150587 - Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Phase 2
Completed NCT03263273 - Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea Phase 2
Completed NCT05343455 - A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) Phase 3
Completed NCT01872715 - Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Phase 4
Completed NCT01784133 - A Twelve Week Safety and Efficacy Study in Rosacea Phase 2
Completed NCT05296629 - A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. Phase 3
Completed NCT05838170 - Study of TP-04 in Participants With Papulopustular Rosacea Phase 2
Recruiting NCT06013371 - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea Phase 2
Completed NCT03564119 - A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea Phase 3
Completed NCT03079531 - Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea Phase 1/Phase 2
Completed NCT01045551 - Open Label Pilot Study of Apremilast in Treatment of Rosacea Phase 2
Completed NCT03448939 - A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Phase 3
Completed NCT05675501 - Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties Phase 1
Withdrawn NCT03883945 - A Safety and Efficacy Study to Evaluate Rosacea Phase 1/Phase 2